{"id":132103,"date":"2025-09-10T06:13:23","date_gmt":"2025-09-10T06:13:23","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/132103\/"},"modified":"2025-09-10T06:13:23","modified_gmt":"2025-09-10T06:13:23","slug":"glp-1-ras-found-to-pose-pregnancy-risks","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/132103\/","title":{"rendered":"GLP-1 RAs found to pose pregnancy risks"},"content":{"rendered":"<p>        <a href=\"https:\/\/www.australianpharmacist.com.au\/wp-content\/uploads\/2025\/09\/GettyImages-1011789360_WEB.jpg\" data-caption=\"\" rel=\"nofollow noopener\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" width=\"696\" height=\"396\" class=\"entry-thumb td-modal-image\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/09\/GettyImages-1011789360_WEB-696x396.jpg\"   alt=\"GLP-1 RAs\" title=\"GettyImages-1011789360_WEB\"\/><\/a><\/p>\n<p>Women of reproductive age using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be at risk of unintended pregnancy, and may be unaware of associated risks to pregnancy and unborn babies.<\/p>\n<p>A new study by Flinders University, which examined records from more than 1.6 million women aged 18\u201349 who attended general practice between 2011 and 2022, found that only one in five (21%) of those with first prescribing of GLP-1 RAs had documented contraceptive use.<\/p>\n<p>The study also found that most prescriptions for GLP-1 RAs are now issued to women without diabetes. In 2022 alone, more than 6,000 women began treatment on GLP-1 RAs, and over 90% of those did not have a type 2 diabetes diagnosis.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-30483\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/09\/Associate-Professor-Luke-Grzeskowiak-Flinders-University.jpg\" alt=\"\" width=\"300\" height=\"300\"  \/>Associate Professor Luke Grzeskowiak<\/p>\n<p>Participants were tracked at the initial stages of GLP-1 RA therapy, with the research team looking at documented evidence of pregnancies over a 6-month period, said lead author and pharmacist, Associate Professor Luke Grzeskowiak.<\/p>\n<p>\u2018[While] limited to data from GP records, one in 25 women aged 18 to 34 years had a documented pregnancy at the time of prescribing,\u2019 he said.<\/p>\n<p>\u2018There will also be pregnancies that the GP might not be aware of, so if anything, what we\u2019re expecting is that this is an underestimate of what\u2019s truly happening.\u2019<\/p>\n<p>Those who were prescribed concurrent contraception were 50% less likely to have a documented pregnancy.<\/p>\n<p>\u2018So we\u2019ve got clear evidence that contraceptive use at the time of initiating these medicines reduces the risk of pregnancies occurring,\u2019 A\/Prof Grzeskowiak said.<\/p>\n<p>Why does GLP-1 RA use increase pregnancy risk?<\/p>\n<p>There are two key reasons: first, it is \u2018well established\u2019 that weight loss can improve fertility.<\/p>\n<p>\u2018Because we know these medicines are very effective at promoting weight loss, it\u2019s highly plausible that they could improve fertility through that mechanism,\u2019 A\/Prof Grzeskowiak said.<\/p>\n<p>There have also been concerns that GLP-1 RAs might impact absorption of the oral contraceptive pill.<\/p>\n<p>In June 2025, the UK\u2019s Medicines and Healthcare products Regulatory Agency issued a <a href=\"https:\/\/www.gov.uk\/government\/news\/women-on-skinny-jabs-must-use-effective-contraception-mhra-urges-in-latest-guidance\" target=\"_blank\" rel=\"noopener nofollow\">regulatory warning<\/a> following case reports of unexpected pregnancies associated with GLP-1 RA use.<\/p>\n<p>\u2018A detailed review [revealed] that the strongest evidence was around potential interaction between tirzepatide and reduced effectiveness of oral contraception,\u2019 A\/Prof Grzeskowiak said.<\/p>\n<p>To date, evidence regarding interactions between GLP-1 RAs and the oral contraceptive pill is limited.<\/p>\n<p>\u2018So the general recommendations around that regulatory warning were for those relying on oral contraceptive methods to also consider using a barrier method,\u2019 he said.<\/p>\n<p>What are the congenital risk factors?<\/p>\n<p>The research also considered potential harms associated with GLP-1 RAs in pregnancy. Key concerns were taken from a University of Amsterdam review of animal studies, cited in the Flinders University study.<\/p>\n<p>\u2018In animals, use of GLP-1 RAs [in pregnancy] led to reductions in foetal growth, impairments in bone development and impaired maternal weight gain,\u2019 A\/Prof Grzeskowiak said.\u00a0<\/p>\n<p>At this stage, the human data are more reassuring.\u00a0<\/p>\n<p>\u2018The studies that have been done have not shown an increased risk of birth defects,\u2019 he said. \u2018But they are still relatively limited in terms of numbers, and we don\u2019t have an examination of the full range of pregnancy outcomes yet,\u2019 he said.<\/p>\n<p>Due to this uncertainty, an abundance of caution is advised.\u00a0<\/p>\n<p>\u2018The recommendations are to not use these medicines during pregnancy, and to avoid the potential for them to be used during pregnancy accidentally,\u2019 A\/Prof Grzeskowiak said. \u2018So it\u2019s important to have a plan around concurrent contraception use, high-quality pre-conception care, and ensure that where pregnancies are planned, everything has been done to optimise pregnancy outcomes.\u2019<\/p>\n<p>What should pharmacists advise patients?<\/p>\n<p>Dispensing GLP-1 RAs provides important opportunities for pharmacists to talk to patients about reproductive health.<\/p>\n<p>For example, when dispensing tirzepatide, access to dispensing data on contraceptive methods enables pharmacists to raise awareness of the potential interaction by initiating an open and unassuming conversation, A\/Prof Grzeskowiak said.\u00a0<\/p>\n<p>\u2018Having a conversation about how that might be addressed means patients can make an informed decision,\u2019 he said. \u2018It might mean changing contraceptive methods or [referring] them back to the GP for a conversation. Or it may be that they\u2019re using contraceptives for non-contraceptive purposes such as acne [management], so there\u2019s a low risk of pregnancy.\u2019<\/p>\n<p>The initiation of therapy is the ideal time to discuss potential risks.<\/p>\n<p>\u2018That way people know what to expect in terms of the medicines,\u2019 he said.<\/p>\n<p>When commencing GLP-1 RAs, patients may also experience profound gastrointestinal adverse effects, including vomiting or diarrhoea.\u00a0<\/p>\n<p>\u2018That in itself can reduce the effectiveness of oral contraception, regardless of any other interactions,\u2019 A\/Prof Grzeskowiak said. \u2018So people should be aware of the side effects of what to expect when starting this and how it might impact on other treatments that they\u2019re using.\u2019<\/p>\n<p>Pharmacists have an important role in engaging patients in conversations about reproductive health, particularly contraception.\u00a0<\/p>\n<p>\u2018Not everyone feels comfortable asking those questions, but there are good training resources, particularly through PSA, around improving pharmacists\u2019 comfort with having those conversations, including around the different types of contraceptive methods,\u2019 he said.<\/p>\n<p>\u2018It\u2019s one thing to start the conversation, but you also need to be armed with various information to be able to continue it, or at least identify when to refer patients back to their medical practitioner or another [healthcare practitioner] to provide that detailed advice.\u2019<\/p>\n","protected":false},"excerpt":{"rendered":"Women of reproductive age using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be at risk of unintended pregnancy,&hellip;\n","protected":false},"author":2,"featured_media":132104,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[64,63,91550,137,91551,7716,2169,555],"class_list":["post-132103","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-au","tag-australia","tag-glp-1-ra","tag-health","tag-oral-contraceptive-pill","tag-ozempic","tag-pregnancy","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/132103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=132103"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/132103\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/132104"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=132103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=132103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=132103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}